Table 1.
Clinical and demographic characteristics of patients, according to KRAS mutation codon location.
| KRAS mutation location | |||||||
|---|---|---|---|---|---|---|---|
| G12A | G12C | G12D | G12R | G12S | G12V | G13D | |
| N, % | 114 (33.8) | 20 (5.9) | 72 (21.4) | 6 (1.8) | 16 (4.7) | 72 (21.4) | 37 (11.0) |
| Median (range) age, years | 65.2 (34.8-81.8) | 59.5 (36.9-81.7) | 64.7 (39.6-80.4) | 61.4 (45.4-79.6) | 58.2 (42.9-83.9) | 67.4 (32.2-82.9) | 64.4 (41.2-87.4) |
| Gender, n (%) | |||||||
| Male | 79 (69.3) | 11 (55.0) | 39 (54.2) | 3 (50) | 14 (87.5) | 39 (54.2) | 27 (73.0) |
| Female | 35 (30.7) | 9 (45.0) | 33 (45.8) | 3 (50) | 2 (12.5) | 33 (45.8) | 10 (27.0) |
| Tumor location, n (%)a | |||||||
| Left colon | 87 (76.3) | 12 (60.0) | 42 (58.3) | 5 (83.3) | 10 (62.5) | 48 (66.7) | 26 (70.3) |
| Right colon | 26 (22.8) | 7 (35) | 28 (38.9) | 0 (0.0) | 4 (25) | 23 (31.9) | 10 (27.0) |
| Surgery, n (%) | 27 (23.7) | 6 (30) | 25 (34.7) | 3 (50) | 5 (31.2) | 18 (25.0) | 10 (27.0) |
| No surgery, n (%) | 87 (76.3) | 14 (70) | 47 (65.3) | 3 (50) | 11 (68.8) | 54 (75.0) | 27 (73.0) |
| Site of metastasis, n (%) | |||||||
| Liver | 44 (38.6) | 7 (35.0) | 24 (33.3) | 4 (66.7) | 7 (43.8) | 27 (37.5) | 14 (37.8) |
| Ganglia + liver | 3 (2.6) | 1 (5.0) | 3 (4.2) | 0 (0.0) | 0 (0.0) | 4 (5.6) | 0 (0.0) |
| Peritoneal + liver | 11 (9.6) | 0 (0.0) | 6 (8.3) | 1 (16.7) | 1 (6.3) | 8 (11.1) | 1 (2.7) |
| Lung + liver | 21 (18.4) | 3 (15.0) | 9 (12.5) | 0 (0.0) | 1 (6.3) | 9 (12.5) | 5 (13.5) |
| Peritoneal | 7 (6.1) | 2 (10.0) | 7 (9.7) | 0 (0.0) | 3 (18.8) | 4 (5.6) | 4 (10.8) |
| Lung | 6 (5.3) | 2 (10.0) | 6 (8.3) | 0 (0.0) | 1 (6.3) | 7 (9.7) | 2 (5.4) |
| Other | 22 (14.3) | 5 (25) | 17 (23.6) | 1 (16.7) | 3 (18.8) | 13 (18.1) | 11 (29.7) |
aTotal number of patients per tumor location including patients whose tumor location was not specifically in the left or the right colon.
Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; N, number of patients.